Exploration of a simple-indicator prediction model for omalizumab efficacy in chronic inducible urticaria. (PubMed, Postepy Dermatol Alergol) - Oct 18, 2026 - "No anaphylaxis occurred and five mild adverse events were recorded. A simple indicator model, strengthened by an early week-4 update, provides accurate and clinically useful prediction of week-12 omalizumab response in CIndU and supports external validation and prospective impact studies."
Journal • Dermatology • Immunology • Urticaria
|
|
Fumin Fang; Lu Wang; Xiaoping Zhang
|